(Q38210265)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Totally drug-resistant tuberculosis and adjunct therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

Totally drug-resistant tuberculosis

17 March 2020

main subject

tuberculosis

0 references

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Shreemanta Parida

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Martin Rao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Markus Maeurer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Shaf Baloch Keshavjee

7

object named as

S Keshavjee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

R Axelsson-Robertson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

N Singh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

I Master

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

A Lutckii

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

J Andersson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

language of work or name

English

0 references

publication date

18 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

17 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

388-405

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

Streptomycin resistance in pulmonary tuberculosis.

17 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Chemotherapy of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

The emergence of drug-resistant tuberculosis in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Clinical and operational value of the extensively drug-resistant tuberculosis definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Totally drug-resistant tuberculosis in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

In vitro susceptibility testing and totally drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Microscopic-observation drug-susceptibility assay for the diagnosis of TB

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Bacteriophage-based assays for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

A role for systems epidemiology in tuberculosis research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Tuberculosis drug resistance mutation database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Use of whole genome sequencing to determine the microevolution of Mycobacterium tuberculosis during an outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

The ins and outs of Mycobacterium tuberculosis drug susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Variable host-pathogen compatibility in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Beijing/W genotype Mycobacterium tuberculosis and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Increased risk of active tuberculosis following acute kidney injury: a nationwide, population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Tuberculosis and cancer: a complex and dangerous liaison

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

From multidrug- to extensively drug-resistant tuberculosis: upward trends as seen from a 15-year nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Nitroimidazoles for the treatment of TB: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

The mechanism of action of PA-824: Novel insights from transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Delamanid for multidrug-resistant pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

MDR-TB has new drug foe after fast-track approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

The oxazolidinones: past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Advances in the development of new tuberculosis drugs and treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Co-administration of IL-1+IL-6+TNF-α with Mycobacterium tuberculosis infected macrophages vaccine induces better protective T cell memory than BCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

A single dose of vitamin D enhances immunity to mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Optimize dietary intake of vitamin D: an epigenetic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Vitamin D: modulator of the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Gene-specific effects of antisense phosphorodiamidate morpholino oligomer-peptide conjugates on Escherichia coli and Salmonella enterica serovar typhimurium in pure culture and in tissue culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

High rate of extensively drug-resistant tuberculosis in Indian AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12264

21 January 2018

Identifiers

DOI

10.1111/JOIM.12264

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24809736%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference